AI Article Synopsis
Article Abstract
Background And Purpose: RC18 is a novel recombinant fusion protein targeting on B lymphocyte stimulator (BLyS). We aimed to develop and qualify a population pharmacokinetics (PopPK) model for RC18 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients, taking into account the mechanistic target-mediated drug disposition (TMDD) process.
Methods: A TMDD model of RC18 was developed using data from two phase I clinical trial (n = 23). The TMDD structural model was developed by simultaneous fitting of the serum free RC18 and serum RC18-BLyS complex. Potential covariates were screened using stepwise method, and predictive performance was qualified using a prediction-corrected visual predictive check (pcVPC) and bootstrap.
Results: A two compartment TMDD model with first order absorption for subcutaneous administration was built. The final model included a significant relationship between distribution volume of the central compartment and body weight. And the baseline of immunoglobulin IgG had significant effect on the baseline of target BLyS. The plots from goodness-of-fit and pcVPC confirmed good predictive performance of this TMDDmodel.
Conclusions: This mechanistic TMDD model integrated the interaction of RC18 with its target BLyS and accurately predicts both RC18 and RC18-BLyS complex profiles in RA and SLE patients. Simulated target change profiles can be used to help guide rational dose regimen selection and used as a biomarker for efficacy evaluation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejps.2021.105704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-dimensional neural ordinary differential equations accounting for inter-individual variability implemented in Monolix and NONMEM.
CPT Pharmacometrics Syst Pharmacol
January 2025
Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland.
Article Synopsis
- * The implementation of low-dimensional NODEs in popular PMX software, Monolix and NONMEM, is detailed, highlighting inter-individual variability and practical applications.
- * Demonstrational datasets in Monolix show that NODEs can produce results comparable to traditional modeling techniques, with accessible model codes provided for reproducibility.
Local depletion of large molecule drugs due to target binding in tissue interstitial space.
CPT Pharmacometrics Syst Pharmacol
December 2024
ESQlabs GmbH, Saterland, Germany.
Drug-target binding determines a drug's pharmacodynamics but can also have a profound impact on a drug's pharmacokinetics, known as target-mediated drug disposition (TMDD). TMDD models describe the influence of drug-target binding and target turnover on unbound drug concentrations and are frequently used for biologics and drugs with nonlinear plasma pharmacokinetics. For drug targets expressed in tissues, the effect of TMDD may not be detected when analyzing plasma concentration curves, but it might still affect tissue concentrations and occupancy.
View Article and Find Full Text PDFInforming pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody.
CPT Pharmacometrics Syst Pharmacol
November 2024
Certara USA, Radnor, Pennsylvania, USA.
Article Synopsis
- - RLYB212 is a human monoclonal antibody in clinical trials aimed at preventing maternal alloimmunization to fetal platelet antigen HPA-1a, which can cause fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- - A target-mediated drug disposition (TMDD) model was developed to analyze how RLYB212 interacts with both the drug's pharmacokinetics (PK) and the dynamics of HPA-1a-positive platelets in HPA-1b/b volunteers.
- - Simulations using the TMDD model identified a dosing regimen of 0.06 mg RLYB212 with a loading dose of 0.12 mg as optimal, ensuring drug levels remain below
Exploring the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery - A Modeling Approach.
AAPS J
October 2024
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, 115 S Grand Ave, Iowa City, Iowa, 52242, USA.
Small-molecule drug development faces the challenge of low success rate. In this paper, we propose one potential cause that may occur in the preclinical phase and has rarely been brought up before - the neglected target-mediated low plasma exposure, and the subsequent lead compound mis-selection due to conventional pharmacokinetic criteria requiring sufficient plasma exposure and desired half-life. To evaluate the concept of target-mediate low plasma exposure, we established a minimal physiologically-based pharmacokinetic (mPBPK) model to evaluate the concentration-time profiles of a group of virtual lead series analogs in plasma and in tissues with and without pharmacological target expression.
View Article and Find Full Text PDFElucidation of DPP-4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss-Newton method.
Clin Transl Sci
October 2024
Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Yokohama-shi, Kanagawa, Japan.
The dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (LNG) exhibits target-mediated drug disposition (TMDD) in clinical settings, characterized by saturable binding to plasma soluble DPP-4 (sDPP-4) and tissue transmembrane DPP-4 (tDPP-4). Previous studies have indicated that saturable renal reabsorption of LNG contributes to its nonlinear urinary excretion observed in humans and wild-type mice, but not in Dpp-4 knockout mice. To elucidate the mechanisms underlying these complex phenomena, including DPP-4-related renal reabsorption of LNG, we employed physiologically-based pharmacokinetic (PBPK) modeling combined with a cluster Gauss-Newton method (CGNM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!